Receptor tyrosine kinases as targets for inhibition of angiogenesis

被引:74
|
作者
Shawver, LK
Lipson, KE
Fong, TAT
McMahon, G
Plowman, GD
Strawn, LM
机构
[1] SUGEN Inc, Redwood City, CA 94063
关键词
D O I
10.1016/S1359-6446(96)10053-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anti-angiogenic agents potentially have broad applications in the clinic. Although most agents now in development are intended ultimately for use as anti-cancer drugs, patients with a range of disorders may benefit in the longer term. The signal recognition and transduction processes involved in controlling angiogenesis are complex and are likely to be dependent on the status of the target endothelial cell in a specific organ or tissue. In this review, the authors focus on signaling interactions that affect microvascular endothelium and the role of growth factors and their receptor tyrosine kinases in the regulation of microvessel physiology as they relate to the angiogenic process.
引用
收藏
页码:50 / 63
页数:14
相关论文
共 50 条
  • [21] Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
    Gschwind, A
    Fischer, OM
    Ullrich, A
    NATURE REVIEWS CANCER, 2004, 4 (05) : 361 - 370
  • [22] Targeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma
    Ou, Wen-Bin
    Hubert, Christopher
    Corson, Joseph M.
    Bueno, Raphael
    Flynn, Daniel L.
    Sugarbaker, David J.
    Fletcher, Jonathan A.
    NEOPLASIA, 2011, 13 (01): : 12 - U26
  • [23] Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapy
    Morel, Marion
    Vanderstraete, Mathieu
    Hahnel, Steffen
    Grevelding, Christoph G.
    Dissous, Colette
    FRONTIERS IN GENETICS, 2014, 5
  • [24] Receptor tyrosine kinases: The main targets for new anticancer therapy
    Drevs, J
    Medinger, M
    Schmidt-Gersbach, C
    Weber, R
    Unger, C
    CURRENT DRUG TARGETS, 2003, 4 (02) : 113 - 121
  • [25] EphA RECEPTOR TYROSINE KINASES AS TARGETS FOR THERAPY IN PAEDIATRIC MEDULLOBLASTOMA
    Carrington, Benjamin
    Al-Ejeh, Fares
    Lim, Yi Chieh
    Ensbey, Kathleen
    Bruce, Zara
    Jamieson, Paul
    Fuchs, Adrian
    Thurecht, Kristofer
    Stringer, Brett
    Boyd, Andrew
    Day, Bryan
    NEURO-ONCOLOGY, 2016, 18 : 153 - 154
  • [26] Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets
    Renne, C.
    Hansmann, M. L.
    Braeuninger, A.
    PATHOLOGE, 2009, 30 (05): : 393 - 400
  • [27] Receptor Tyrosine Kinases as Therapeutic Targets for Alcohol Use Disorder
    Hamada, Kana
    Lasek, Amy W.
    NEUROTHERAPEUTICS, 2020, 17 (01) : 4 - 16
  • [28] Mer and Axl receptor tyrosine kinases are novel therapeutic targets in NSCLC
    Linger, Rachel M. A.
    Middleton, Deryck H. G.
    Migdall, Justine
    Cohen, Rebecca A.
    Mehta, Atul
    Kim, Grace K.
    Franklin, Wilbur A.
    Merrick, Daniel T.
    Liang, Xiayuan
    Jedlicka, Paul
    Heasley, Lynn E.
    Graham, Douglas K.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S235 - S235
  • [29] Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer
    José Baselga
    John Mendelsohn
    Journal of Mammary Gland Biology and Neoplasia, 1997, 2 : 165 - 174
  • [30] SEARCHING FOR RECEPTOR TYROSINE KINASES AS MOLECULAR TARGETS IN BREAST CANCER TREATMENT
    Roussidis, A. E.
    Theocharis, A. D.
    Karamanos, N. K.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3615 - 3615